サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1426440

急性リンパ性-リンパ芽球性白血病治療薬の世界市場レポート 2024

Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
急性リンパ性-リンパ芽球性白血病治療薬の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

急性リンパ性-リンパ芽球性白血病治療薬の市場規模は、今後数年間で大幅な成長が見込まれています。2028年には5.4%の年間複合成長率（CAGR）で35億1,000万米ドルに成長すると予想されます。予測期間で予想される成長は、個々の患者に合わせた個別化医療アプローチ、新規治療薬へのアクセスの拡大、世界の健康への取り組み、患者擁護と意識の向上、規制経路の合理化に起因すると考えられます。予測期間中に予想される注目すべき動向には、支持療法の革新、共同調査の取り組み、診断技術の進歩、CAR-T細胞療法の出現、急性リンパ性-リンパ芽球性白血病治療のための生物学的製剤の革新などが含まれます。

急性リンパ性-リンパ芽球性白血病（ALL）治療薬市場の予想される成長は、遺伝的疾患の有病率の増加によって推進されています。個人のDNAまたは遺伝子の突然変異に起因する遺伝的状態は、異常な細胞増殖を引き起こし、がんを引き起こす可能性があります。急性リンパ性-リンパ芽球性白血病の遺伝子検査は、特定の遺伝子異常を特定するのに役立ち、治療上の決定に役立ちます。たとえば、英国に本拠を置く慈善団体Gene Peopleは、子どもの遺伝的疾患の推定有病率は25人に1人と報告しており、英国では240万人以上が罹患していることを示しています。この有病率は、ALL治療薬市場の成長を促進する上での遺伝的疾患の役割を浮き彫りにしています。

骨髄移植の需要の高まりは、急性リンパ性-リンパ芽球性白血病治療薬市場の重要な促進力となる見込みです。損傷または病気の骨髄を健康な造血幹細胞に置き換える骨髄移植は、より高い寛解率や治癒の可能性などの利点をもたらします。米国では、2023年6月の保健資源サービス局のデータによると、2021年に5,073件の無関係な骨髄と臍帯血移植、4,276件の関連骨髄と臍帯血移植が行われたことが明らかになりました。登録ドナー数が2021年の928万5,029人から、2022年には947万5,534人に増加していることから、需要の増加は明らかです。これは、ALL治療薬市場の成長を促進する骨髄移植の影響を強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の急性リンパ性-リンパ芽球性白血病（ALL）治療薬市場の促進要因の抑制要因
    • 市場の促進要因
    • 市場の抑制要因
  • 世界の急性リンパ性-リンパ芽球性白血病（ALL）治療薬の市場規模実績と成長、2018年～2023年
  • 世界の急性リンパ性-リンパ芽球性白血病（ALL）治療薬の市場規模と成長予測、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の急性リンパ性-リンパ芽球性白血病（ALL）治療薬市場、治療法別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 化学療法
  • 標的療法
  • 放射線治療
  • 幹細胞移植
  • 世界の急性リンパ性-リンパ芽球性白血病（ALL）治療薬市場、診断別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 生検と骨髄穿刺
  • 全血球計算（CBC）と微分
  • フィラデルフィア染色体の存在
  • 脊髄穿刺と脳脊髄液（CSF）の分析
  • 免疫表現型検査またはフローサイトメトリーによる表現型検査
  • ポリメラーゼ連鎖反応（PCR）
  • 世界の急性リンパ性-リンパ芽球性白血病（ALL）治療薬市場、細胞タイプ別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • フィラデルフィア染色体
  • 前駆型B細胞性急性リンパ芽球性白血病（ALL）
  • T細胞急性リンパ芽球性白血病（ALL）
  • 世界の急性リンパ性-リンパ芽球性白血病（ALL）治療薬市場、投与経路別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 経口
  • 非経口
  • 世界の急性リンパ性-リンパ芽球性白血病（ALL）治療薬市場、年齢層別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 小児
  • 大人

第7章 地域と国の分析

  • 世界の急性リンパ性-リンパ芽球性白血病（ALL）治療薬市場、地域別、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 世界の急性リンパ性-リンパ芽球性白血病（ALL）治療薬市場、国別、実績と予測、2018年～2023年、2023年～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 急性リンパ性-リンパ芽球性白血病（ALL）治療薬市場の競合情勢
  • 急性リンパ性-リンパ芽球性白血病（ALL）治療薬市場の企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • AbbVie Inc.
    • Novartis AG
    • Sanofi SA

第31章 その他の大手と革新的な企業

  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Baxter International Inc.
  • Astellas Pharma Inc.
  • Eisai Co. Ltd.
  • Jazz Pharmaceuticals Inc.
  • Ono Pharmaceutical Co. Ltd.
  • Genmab A/S
  • Kite Pharma
  • ADC Therapeutics
  • Kiadis Pharma
  • SymBio Pharmaceuticals Limited

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13452

Acute lymphocytic leukemia (ALL), also known as acute lymphoblastic leukemia, is a rapidly progressing cancer that originates in the bone marrow, where blood cells are produced. It predominantly affects immature white blood cells called lymphocytes, which play a crucial role in the body's immune system.

The primary therapeutic modalities for acute lymphocytic-lymphoblastic leukemia include chemotherapy, targeted therapy, radiation therapy, and stem cell transplantation. Chemotherapy is a systemic treatment that utilizes drugs to destroy or inhibit the growth of rapidly dividing cells, including cancer cells. The diagnostic procedures for ALL involve various tests such as biopsy and bone marrow aspiration, complete blood count (CBC) and differential, assessment for the presence of the Philadelphia chromosome, spinal tap and cerebrospinal fluid (CSF) analysis, and immunophenotyping or phenotyping by flow cytometry. Additionally, molecular diagnostic techniques such as polymerase chain reaction (PCR) are used. Acute lymphocytic-lymphoblastic leukemia can be diagnosed in various cell types, including the Philadelphia chromosome, precursor B-cell ALL, and T-cell ALL. The administration routes for treatment include oral and parenteral, catering to both pediatric and adult age groups.

The acute lymphocytic-lymphoblastic leukemia therapeutics market research report is one of a series of new reports from The Business Research Company that provides acute lymphocytic-lymphoblastic leukemia therapeutics market statistics, including acute lymphocytic-lymphoblastic leukemia therapeutics industry global market size, regional shares, competitors with an acute lymphocytic-lymphoblastic leukemia therapeutics market share, detailed acute lymphocytic-lymphoblastic leukemia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the acute lymphocytic-lymphoblastic leukemia therapeutics industry. This acute lymphocytic-lymphoblastic leukemia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute lymphocytic-lymphoblastic leukemia therapeutics market size has grown strongly in recent years. It will grow from $2.68 billion in 2023 to $2.85 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth observed in the historical period can be attributed to various factors, including advancements in chemotherapy, the development of biological and targeted therapies, ongoing research in pediatric oncology, improvements in supportive care, and the utilization of stem cell transplantation in the treatment of acute lymphocytic-lymphoblastic leukemia.

The acute lymphocytic-lymphoblastic leukemia therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.51 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The anticipated growth in the forecast period can be attributed to personalized medicine approaches tailored to individual patients, expanded access to novel therapeutic agents, global health initiatives, increased patient advocacy and awareness, and streamlined regulatory pathways. Noteworthy trends expected in the forecast period include innovation in supportive care, collaborative research efforts, advancements in diagnostic technologies, the emergence of CAR-T cell therapies, and innovations in biologics for the treatment of acute lymphocytic-lymphoblastic leukemia.

The anticipated growth of the acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market is driven by the increasing prevalence of genetic conditions. Genetic conditions, resulting from mutations in an individual's DNA or genes, can lead to abnormal cell growth, potentially causing cancer. Genetic testing in acute lymphocytic-lymphoblastic leukemia aids in identifying specific genetic anomalies, informing therapeutic decisions. For example, Gene People, a UK-based charity, reported an estimated prevalence of 1 in 25 for genetic conditions in children, indicating over 2.4 million affected individuals in the UK. This prevalence highlights the role of genetic conditions in propelling the growth of the ALL therapeutics market.

The growing demand for bone marrow transplantation is poised to be a significant driver for the acute lymphocytic-lymphoblastic leukemia therapeutics market. Bone marrow transplantation, replacing damaged or diseased bone marrow with healthy hematopoietic stem cells, offers benefits such as higher remission rates and potential cures. In the United States, Health Resources and Services Administration data from June 2023 revealed 5,073 unrelated and 4,276 related bone marrow and cord blood transplants in 2021. The increasing demand is evident from the rise in registered donors from 9,285,029 in 2021 to 9,475,534 in 2022. This underscores the impact of bone marrow transplantation in driving the growth of the ALL therapeutics market.

The high cost of treatment is expected to impede the growth of the acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market. This financial burden includes the costs associated with diagnosing and treating leukemia, varying depending on the leukemia type and treatment phase. According to the National Cancer Institute's August 2023 data, annualized average costs for medical services and oral prescription drugs in the United States show considerable variation. The high treatment costs pose challenges for patients and their families, hindering the market's growth.

Major companies in the acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market are actively developing innovative therapies to address consumer needs. Tecartus (brexucabtagene autoleucel) by Kite Pharma is a notable example, utilizing chimeric antigen receptor (CAR) T-cell therapy. Tecartus, approved by the Food and Drug Administration in November 2021, is a CD19-directed genetically modified autologous T-cell immunotherapy. This CAR T-cell therapy has expanded treatment options for adults with ALL, showcasing Kite Pharma's expertise in cell therapy and contributing to revenue growth.

In April 2021, Artios Pharma Limited, a UK-based pharmaceutical company, collaborated with Novartis AG to develop DDR cancer therapies. This collaboration combines Novartis' radioligand therapeutics with Artios Pharma's discovery platform to target DNA damage response (DDR) and advance novel cancer medicines. Novartis AG's contributions to the field include advancements in treatments for blood malignancies such as acute lymphocytic or lymphoblastic leukemia (ALL).

Major companies operating in the acute lymphocytic-lymphoblastic leukemia therapeutics market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Astellas Pharma Inc., Eisai Co. Ltd., Jazz Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Genmab A/S, Kite Pharma, ADC Therapeutics, Kiadis Pharma, SymBio Pharmaceuticals Limited, Celyad Oncology SA, Precigen Inc., Leadiant Biosciences Inc., Medexus Pharma Inc., Spectrum Pharmaceuticals Inc., OBI Pharma Inc.

North America was the largest region in the acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute lymphocytic-lymphoblastic leukemia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the acute lymphocytic-lymphoblastic leukemia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market includes revenues earned by entities by providing services such as laboratory testing, molecular diagnostics, chemotherapy administration, targeted therapy, blood and platelet transfusions, and genetic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market also includes sales of Arranon (nelarabine), Asparaginase erwinia chrysanthemi, Asparlas (calaspargase pegol-mknl), Besponsa (inotuzumab ozogamicin), and Blincyto (blinatumomab). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute lymphocytic-lymphoblastic leukemia therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute lymphocytic-lymphoblastic leukemia therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute lymphocytic-lymphoblastic leukemia therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Therapy Type: Chemotherapy; Targeted Therapy; Radiation Therapy; Stem Cell Transplantation
  • 2) By Diagnosis: Biopsy And Bone Marrow Aspiration; Complete Blood Count (CBC) And Differential; Presence Of Philadelphia Chromosome; Spinal Tap And Cerebrospinal Fluid (CSF) Analysis; Immunophenotyping Or Phenotyping By Flow Cytometry; Polymerase Chain Reaction (PCR)
  • 3) By Cell Type: Philadelphia Chromosome; Precursor B-Cell Acute Lymphoblastic Leukemia (ALL); T-Cell Acute Lymphoblastic Leukemia (ALL)
  • 4) By Route Of Administration: Oral; Parenteral
  • 5) By Age Group: Pediatrics; Adults
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Novartis AG; Sanofi S.A.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Characteristics

3. Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Trends And Strategies

4. Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Size and Growth

  • 5.1. Global Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Segmentation

  • 6.1. Global Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Stem Cell Transplantation
  • 6.2. Global Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Biopsy And Bone Marrow Aspiration
  • Complete Blood Count (CBC) And Differential
  • Presence Of Philadelphia Chromosome
  • Spinal Tap And Cerebrospinal Fluid (CSF) Analysis
  • Immunophenotyping Or Phenotyping By Flow Cytometry
  • Polymerase Chain Reaction (PCR)
  • 6.3. Global Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Philadelphia Chromosome
  • Precursor B-Cell Acute Lymphoblastic Leukemia (ALL)
  • T-Cell Acute Lymphoblastic Leukemia (ALL)
  • 6.4. Global Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • 6.5. Global Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pediatrics
  • Adults

7. Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Regional And Country Analysis

  • 7.1. Global Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 8.1. Asia-Pacific Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 9.1. China Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Overview
  • 9.2. China Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 10.1. India Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 11.1. Japan Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Overview
  • 11.2. Japan Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 12.1. Australia Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 13.1. Indonesia Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 14.1. South Korea Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Overview
  • 14.2. South Korea Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 15.1. Western Europe Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Overview
  • 15.2. Western Europe Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 16.1. UK Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 17.1. Germany Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 18.5. France Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.6. France Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.7. France Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 19.9. Italy Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.10. Italy Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.11. Italy Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 20.13. Spain Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.14. Spain Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 21.1. Eastern Europe Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Overview
  • 21.2. Eastern Europe Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 22.1. Russia Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 23.1. North America Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Overview
  • 23.2. North America Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 24.1. USA Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Overview
  • 24.2. USA Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 25.1. Canada Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Overview
  • 25.2. Canada Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 26.1. South America Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Overview
  • 26.2. South America Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 27.1. Brazil Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 28.1. Middle East Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Overview
  • 28.2. Middle East Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

  • 29.1. Africa Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Overview
  • 29.2. Africa Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Competitive Landscape
  • 30.2. Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. AbbVie Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Sanofi S.A.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Other Major And Innovative Companies

  • 31.1. Bristol-Myers Squibb Company
  • 31.2. GlaxoSmithKline plc
  • 31.3. Takeda Pharmaceutical Company Limited
  • 31.4. Gilead Sciences Inc.
  • 31.5. Amgen Inc.
  • 31.6. Baxter International Inc.
  • 31.7. Astellas Pharma Inc.
  • 31.8. Eisai Co. Ltd.
  • 31.9. Jazz Pharmaceuticals Inc.
  • 31.10. Ono Pharmaceutical Co. Ltd.
  • 31.11. Genmab A/S
  • 31.12. Kite Pharma
  • 31.13. ADC Therapeutics
  • 31.14. Kiadis Pharma
  • 31.15. SymBio Pharmaceuticals Limited

32. Global Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Competitive Benchmarking

33. Global Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

35. Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Future Outlook and Potential Analysis

  • 35.1 Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer